208 related articles for article (PubMed ID: 35398293)
1. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.
Chiba K; Okazaki N; Kurogi A; Watanabe T; Mori A; Suzuki N; Adachi K; Era M; Yokota K; Inoue T; Yabe Y; Furukawa K; Kondo C; Tsuda K; Ota S; Isobe Y; Miyazaki S; Morimoto S; Sato S; Nakashima S; Tashiro S; Yonekura A; Tomita M; Osaki M
Bone; 2022 Jul; 160():116416. PubMed ID: 35398293
[TBL] [Abstract][Full Text] [Related]
2. Bone microstructure in healthy men measured by HR-pQCT: Age-related changes and their relationships with DXA parameters and biochemical markers.
Doi M; Chiba K; Okazaki N; Kondo C; Yamada S; Yokota K; Yonekura A; Tomita M; Osaki M
Bone; 2022 Jan; 154():116252. PubMed ID: 34743043
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT.
Agarwal S; Shiau S; Kamanda-Kosseh M; Bucovsky M; Kil N; Lappe JM; Stubby J; Recker RR; Guo XE; Shane E; Cohen A
J Bone Miner Res; 2023 Jan; 38(1):35-47. PubMed ID: 36335582
[TBL] [Abstract][Full Text] [Related]
4. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study).
Tsai JN; Uihlein AV; Burnett-Bowie SM; Neer RM; Derrico NP; Lee H; Bouxsein ML; Leder BZ
J Clin Endocrinol Metab; 2016 May; 101(5):2023-30. PubMed ID: 26964731
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study.
Paggiosi MA; Yang L; Blackwell D; Walsh JS; McCloskey E; Peel N; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1367-1378. PubMed ID: 29520607
[TBL] [Abstract][Full Text] [Related]
6. Impaired bone mineral density and microarchitecture in female adolescents with IgE-mediated cow's milk allergy.
Yonamine GH; Domiciano DS; Takayama L; Castro APBM; Pereira RMR; Pastorino AC
Arch Osteoporos; 2024 May; 19(1):40. PubMed ID: 38773042
[TBL] [Abstract][Full Text] [Related]
7. Relationships between QUS and HR-pQCT, DXA, and bone turnover markers.
Niimi R; Chiba K; Okazaki N; Yonekura A; Tomita M; Osaki M
J Bone Miner Metab; 2022 Sep; 40(5):790-800. PubMed ID: 35691990
[TBL] [Abstract][Full Text] [Related]
8. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Macdonald HM; Nishiyama KK; Hanley DA; Boyd SK
Osteoporos Int; 2011 Jan; 22(1):357-62. PubMed ID: 20458576
[TBL] [Abstract][Full Text] [Related]
9. Poor bone microarchitecture in older men with impaired physical performance--the STRAMBO study.
Blaizot S; Boutroy S; Vilayphiou N; Boonen S; Chapurlat R; Szulc P
Osteoporos Int; 2012 Dec; 23(12):2785-96. PubMed ID: 22290241
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
Schafer AL; Burghardt AJ; Sellmeyer DE; Palermo L; Shoback DM; Majumdar S; Black DM
Osteoporos Int; 2013 Oct; 24(10):2591-601. PubMed ID: 23589163
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling.
Winzenrieth R; Ominsky MS; Wang Y; Humbert L; Weiss RJ
Osteoporos Int; 2021 Mar; 32(3):575-583. PubMed ID: 33496831
[TBL] [Abstract][Full Text] [Related]
12. Bone density and microarchitecture in hepatitis C and HIV-coinfected postmenopausal minority women.
T Yin M; RoyChoudhury A; Nishiyama K; Lang T; Shah J; Olender S; Ferris DC; Zeana C; Sharma A; Zingman B; Bucovsky M; Colon I; Shane E
Osteoporos Int; 2018 Apr; 29(4):871-879. PubMed ID: 29387910
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.
Tsai JN; Uihlein AV; Burnett-Bowie SA; Neer RM; Zhu Y; Derrico N; Lee H; Bouxsein ML; Leder BZ
J Bone Miner Res; 2015 Jan; 30(1):39-45. PubMed ID: 25043459
[TBL] [Abstract][Full Text] [Related]
14. Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis.
Winzenrieth R; Humbert L; Boxberger JI; Weiss RJ; Wang Y; Kostenuik P
J Clin Densitom; 2022; 25(3):392-400. PubMed ID: 35033435
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.
Kleerekoper M; Greenspan SL; Lewiecki EM; Miller PD; Kendler DL; Maricic M; Keaveny TM; Kopperdahl DL; Ruff VA; Wan X; Janos B; Krohn K
J Bone Joint Surg Am; 2014 Jun; 96(11):e90. PubMed ID: 24897747
[TBL] [Abstract][Full Text] [Related]
16. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case-control study using HR-pQCT.
Hansen S; Beck Jensen JE; Rasmussen L; Hauge EM; Brixen K
J Bone Miner Res; 2010 Sep; 25(9):1941-7. PubMed ID: 20499376
[TBL] [Abstract][Full Text] [Related]
17. Performance of HR-pQCT, DXA, and FRAX in the discrimination of asymptomatic vertebral fracture in postmenopausal Chinese women.
Huang M; Hung VW; Li TK; Law SW; Wang Y; Chen S; Qin L
Arch Osteoporos; 2021 Sep; 16(1):125. PubMed ID: 34480663
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
Burghardt AJ; Kazakia GJ; Sode M; de Papp AE; Link TM; Majumdar S
J Bone Miner Res; 2010 Dec; 25(12):2558-71. PubMed ID: 20564242
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension.
Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Tsai JN; Leder BZ
J Bone Miner Res; 2023 Jan; 38(1):26-34. PubMed ID: 36333954
[TBL] [Abstract][Full Text] [Related]
20. Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT Study.
Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Leder BZ; Tsai JN
J Bone Miner Res; 2021 Jan; 36(1):41-51. PubMed ID: 32790196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
